To address the challenge of resistance in KRAS G12C inhibitor therapies for NSCLC, we developed KRAS G12C inhibitor-resistant tumor models. Utilizing CRISPR/Cas9, we introduced secondary KRAS mutations to analyze growth rates and resistance profiles. These preclinical models enable the evaluation of new anticancer therapies, providing a crucial tool to overcome resistance and enhance clinical outcomes for patients with KRAS-targeted treatments.
Developing KRAS G12C Inhibitor-Resistant Tumor Models for Efficacy Evaluation of Next-Generation Anticancer Therapies
We offer specialized models, either acquired from clinics or engineered in-house, and advanced disease models such as brain orthotopic PDX models and experimental CDX models for metastatic research. These models provide vital insights into metastatic progression and therapeutic responses.
Our OrganoidXplore™ application offers a wide-ranging cancer panel covering seven indications. This extensive selection enables the creation of personalized research panels, delivering targeted resources for lung and colorectal cancer research, and panels centered on key mutations. Our integrated services ensure that your research benefits from the most accurate and clinically relevant models available, paving the way for breakthroughs in KRAS-targeted therapies.
Studies
Completed
This data point indicates the total number of studies in Q2 2023 that the CSAT, Customer Effort, and Customer Expectation scores are measured against.
Studies
Completed
Customer
Satisfaction
Also known as CSAT, this metric indicates how satisfied customers are with the complete Crown Bioscience customer experience.
Customer
Satisfaction
Customer
Effort
The Customer Effort Score (CES) is a metric that measures how easy it was to work with Crown Bioscience.
Customer
Effort
KRASG12C Inhibition Synergizes with Checkpoint Blockade in KRASG12C-Mutated Tumor Model
